Aicardi-Goutières syndrome: A model disease for systemic autoimmunity

Clinical and Experimental Immunology

Volumn 175, Issue 1, 2014, Pages 17-24

  Lee Kirsch, M A ^a   Wolf, C ^a   Gunther C ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Aicardi Gouti res syndrome; Autoimmunity; Nucleic acid sensing; Systemic lupus erythematosus; Type I interferon

Indexed keywords

ADENOSINE DEAMINASE ACTING ON RNA 1; AUTOANTIBODY; BELIMUMAB; CELL NUCLEUS ANTIGEN; CORTICOSTEROID; CYTOSTATIC AGENT; DNA; EXONUCLEASE; HYDROXYCHLOROQUINE; NUCLEIC ACID; PROTEIN; RIBONUCLEASE H; RIBONUCLEASE H2; RNA; SAM DOMAIN AND HD DOMAIN CONTAINING PROTEIN 1; THREE PRIME REPAIR EXONUCLEASE 1; UNCLASSIFIED DRUG;

AICARDI GOUTIERES SYNDROME; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; CLINICAL TRIAL (TOPIC); DEGRADATION; DNA REPAIR; DNA REPLICATION; HUMAN; INNATE IMMUNITY; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT;

AICARDI-GOUTIÈRES SYNDROME; AUTOIMMUNITY; NUCLEIC ACID SENSING; SYSTEMIC LUPUS ERYTHEMATOSUS; TYPE I INTERFERON;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; DNA; DNA REPAIR; DNA REPLICATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; NERVOUS SYSTEM MALFORMATIONS;

EID: 84888858547     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12160     Document Type: Article

References (86)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358:929-939.
2. Tan EM, Cohen AS, Fries JF etal. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-1277.
3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
4. Alarcon GS, McGwin G, Jr, Roseman JM etal. Systemic lupus erythematosus in three ethnic groups. XIX. Natural history of the accrual of the American College of Rheumatology criteria prior to the occurrence of criteria diagnosis. Arthritis Rheum 2004; 51:609-615.
5. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006; 15:308-318.
6. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010; 6:538-546.
7. Rhodes B, Vyse TJ. General aspects of the genetics of SLE. Autoimmunity 2007; 40:550-559.
8. Bijl M, Kallenberg CG. Ultraviolet light and cutaneous lupus. Lupus 2006; 15:724-727.
9. Harley JB, Harley IT, Guthridge JM, James JA. The curiously suspicious: a role for Epstein-Barr virus in lupus. Lupus 2006; 15:768-777.
10. Morel L. Genetics of SLE: evidence from mouse models. Nat Rev Rheumatol 2010; 6:348-357.
11. Harley IT, Kaufman KM, Langefeld CD, Harley JB, Kelly JA. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet 2009; 10:285-290.
12. Manjarrez-Orduno N, Marasco E, Chung SA etal. CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nat Genet 2012; 44:1227-1230.
13. Michels AW, Gottlieb PA. Autoimmune polyglandular syndromes. Nat Rev Endocrinol 2010; 6:270-277.
14. Aicardi J, Goutieres F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 1984; 15:49-54.
15. Lebon P, Badoual J, Ponsot G, Goutieres F, Hemeury-Cukier F, Aicardi J. Intrathecal synthesis of interferon-alpha in infants with progressive familial encephalopathy. J Neurol Sci 1988; 84:201-208.
16. Tolmie JL, Shillito P, Hughes-Benzie R, Stephenson JB. The Aicardi-Goutieres syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). J Med Genet 1995; 32:881-884.
17. Ramantani G, Kohlhase J, Hertzberg C etal. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutieres syndrome. Arthritis Rheum 2010; 62:1469-1477.
18. Crow YJ, Hayward BE, Parmar R etal. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat Genet 2006; 38:917-920.
19. Crow YJ, Leitch A, Hayward BE etal. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nat Genet 2006; 38:910-916.
20. Rice GI, Bond J, Asipu A etal. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 2009; 41:829-832.
21. Rice GI, Kasher PR, Forte GM etal. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet 2012; 44:1243-1248.
22. Lee-Kirsch MA, Gong M, Schulz H etal. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet 2006; 79:731-737.
23. Rice G, Newman WG, Dean J etal. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet 2007; 80:811-815.
24. Lee-Kirsch MA, Chowdhury D, Harvey S etal. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med 2007; 85:531-537.
25. Richards A, Van Den Maagdenberg AM, Jen JC etal. C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 2007; 39:1068-1070.
26. Haaxma CA, Crow YJ, van Steensel MA etal. A de novo p.Asp18Asn mutation in TREX1 in a patient with Aicardi-Goutières syndrome. Am J Med Genet A 2010; 152A:2612-2617.
27. Tungler V, Silver RM, Walkenhorst H, Gunther C, Lee-Kirsch MA. Inherited or de novo mutation affecting aspartate 18 of TREX1 results in either familial chilblain lupus or Aicardi-Goutières syndrome. Br J Dermatol 2012; 167:212-214.
28. Ravenscroft JC, Suri M, Rice GI, Szynkiewicz M, Crow YJ. Autosomal dominant inheritance of a heterozygous mutation in SAMHD1 causing familial chilblain lupus. Am J Med Genet A 2011; 155A:235-237.
29. Lee-Kirsch MA, Gong M, Chowdhury D etal. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007; 39:1065-1067.
30. de Vries B, Steup-Beekman GM, Haan J etal. TREX1 gene variant in neuropsychiatric systemic lupus erythematosus. Ann Rheum Dis 2010; 69:1886-1887.
31. Namjou B, Kothari PH, Kelly JA etal. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun 2011; 12:270-279.
32. Mazur DJ, Perrino FW. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3′->5′ exonucleases. J Biol Chem 1999; 274:19655-19660.
33. Chowdhury D, Beresford PJ, Zhu P etal. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol Cell 2006; 23:133-142.
34. Yang YG, Lindahl T, Barnes DE. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 2007; 131:873-886.
35. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008; 134:587-598.
36. Deininger PL, Moran JV, Batzer MA, Kazazian HH Jr. Mobile elements and mammalian genome evolution. Curr Opin Genet Dev 2003; 13:651-658.
37. Hancks DC, Kazazian HH Jr. Active human retrotransposons: variation and disease. Curr Opin Genet Dev 2012; 22:191-203.
38. Dewannieux M, Dupressoir A, Harper F, Pierron G, Heidmann T. Identification of autonomous IAP LTR retrotransposons mobile in mammalian cells. Nat Genet 2004; 36:534-539.
39. Young GR, Eksmond U, Salcedo R, Alexopoulou L, Stoye JP, Kassiotis G. Resurrection of endogenous retroviruses in antibody-deficient mice. Nature 2012; 491:774-778.
40. Yu P, Lubben W, Slomka H etal. Nucleic acid-sensing Toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumors. Immunity 2012; 37:867-879.
41. Morita M, Stamp G, Robins P etal. Gene-targeted mice lacking the Trex1 (DNase III) 3′->5′ DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol 2004; 24:6719-6727.
42. Gall A, Treuting P, Elkon KB etal. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 2012; 36:120-131.
43. Beck-Engeser GB, Eilat D, Wabl M. An autoimmune disease prevented by anti-retroviral drugs. Retrovirology 2011; 8:91.
44. Chon H, Vassilev A, DePamphilis ML etal. Contributions of the two accessory subunits, RNASEH2B and RNASEH2C, to the activity and properties of the human RNase H2 complex. Nucleic Acids Res 2009; 37:96-110.
45. Bubeck D, Reijns MA, Graham SC, Astell KR, Jones EY, Jackson AP. PCNA directs type 2 RNase H activity on DNA replication and repair substrates. Nucleic Acids Res 2011; 39:3652-3666.
46. Nick McElhinny SA, Kumar D, Clark AB etal. Genome instability due to ribonucleotide incorporation into DNA. Nat Chem Biol 2010; 6:774-781.
47. Reijns MA, Rabe B, Rigby RE etal. Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development. Cell 2012; 149:1008-1022.
48. Hiller B, Achleitner M, Glage S, Naumann R, Behrendt R, Roers A. Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity. J Exp Med 2012; 209:1419-1426.
49. Sparks JL, Chon H, Cerritelli SM etal. RNase H2-initiated ribonucleotide excision repair. Mol Cell 2012; 47:980-986.
50. Kim N, Huang SN, Williams JS etal. Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science 2011; 332:1561-1564.
51. Goldstone DC, Ennis-Adeniran V, Hedden JJ etal. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011; 480:379-382.
52. Hrecka K, Hao C, Gierszewska M etal. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474:658-661.
53. Laguette N, Sobhian B, Casartelli N etal. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474:654-657.
54. Lahouassa H, Daddacha W, Hofmann H etal. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012; 13:223-228.
55. Cribier A, Descours B, Valadao AL, Laguette N, Benkirane M. Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. Cell Rep 2013; 3:1036-1043.
56. White TE, Brandariz-Nunez A, Valle-Casuso JC etal. The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. Cell Host Microbe 2013; 13:441-451.
57. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 2010; 11:1005-1013.
58. Goncalves A, Karayel E, Rice GI etal. SAMHD1 is a nucleic-acid binding protein that is mislocalized due to Aicardi-Goutières syndrome-associated mutations. Hum Mutat 2012; 33:1116-1122.
59. Tungler V, Staroske W, Kind B etal. Single-stranded nucleic acids promote SAMHD1 complex formation. J Mol Med (Berl) 2013; 91:759-770.
60. Beloglazova N, Flick R, Tchigvintsev A etal. Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutières syndrome and HIV-1 restriction. J Biol Chem 2013; 288:8101-8110.
61. Zhang X, Mathews CK. Natural DNA precursor pool asymmetry and base sequence context as determinants of replication fidelity. J Biol Chem 1995; 270:8401-8404.
62. Wang Q. RNA editing catalyzed by ADAR1 and its function in mammalian cells. Biochemistry (Mosc) 2011; 76:900-911.
63. Wang Q, Khillan J, Gadue P, Nishikura K. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science 2000; 290:1765-1768.
64. Iizasa H, Nishikura K. A new function for the RNA-editing enzyme ADAR1. Nat Immunol 2009; 10:16-18.
65. Samuel CE. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 2011; 411:180-193.
66. Baechler EC, Batliwalla FM, Karypis G etal. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100:2610-2615.
67. Ronnblom L, Alm GV, Eloranta ML. Type I interferon and lupus. Curr Opin Rheumatol 2009; 21:471-477.
68. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001; 1:147-153.
69. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416:603-607.
70. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004; 50:1861-1872.
71. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6:823-835.
72. Cook HT, Botto M. Mechanisms of Disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006; 2:330-337.
73. Atianand MK, Fitzgerald KA. Molecular basis of DNA recognition in the immune system. J Immunol 2013; 190:1911-1918.
74. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013; 339:786-791.
75. Hornung V, Latz E. Intracellular DNA recognition. Nat Rev Immunol 2010; 10:123-130.
76. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 2000; 25:177-181.
77. Yasutomo K, Horiuchi T, Kagami S etal. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 2001; 28:313-314.
78. Nagata S. Autoimmune diseases caused by defects in clearing dead cells and nuclei expelled from erythroid precursors. Immunol Rev 2007; 220:237-250.
79. Al-Mayouf SM, Sunker A, Abdwani R etal. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet 2011; 43:1186-1188.
80. Hasan M, Koch J, Rakheja D etal. Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes. Nat Immunol 2013; 14:61-71.
81. Eisenberg R. Why can't we find a new treatment for SLE? J Autoimmun 2009; 32:223-230.
82. Wallace DJ. Advances in drug therapy for systemic lupus erythematosus. BMC Med 2010; 8:77.
83. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-316.
84. Horowitz DL, Furie R. Belimumab is approved by the FDA: what more do we need to know to optimize decision making? Curr Rheumatol Rep 2012; 14:318-323.
85. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun 2010; 35:225-231.
86. Eloranta ML, Franck-Larsson K, Lovgren T etal. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010; 69:1396-1402.